List view / Grid view
The University at Buffalo has received a $2.3 million grant from the US National Cancer Institute to identify metabolic vulnerabilities of ovarian cancer and to develop potential treatments for the disease.
Researchers have found how ovarian cancer tumours defy immunotherapy, identifying new molecular targets that might boost immune response.
New research has discovered metabolic mechanisms that contribute to how ovarian cancer escapes from immune attack and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
Scientists have uncovered the crucial role of the enzyme NMNAT-2 in ovarian cancers, as well as other biomarkers that could lead to treatments.
A new radiopharmaceutical compound has shown success at treating ovarian cancer in mice and in vitro studies.
A range of imaging and computational techniques were used by researchers to discover the structure of the PH domain of PLEKHA7.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.
Using a mouse model, researchers found that cancer progression led to fewer skeletal muscle ribosomes, likely explaining muscle wasting.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
Researchers say this is the first time that CRISPR-Cas9 gene editing has been used to treat cancer effectively in a living animal and that the technique could be revolutionary.
Researchers have developed a new self-assembling three-dimensional (3D) ovarian cancer tumour model to recreate the in vitro disease more accurately.
Researchers testing 2-deoxy-D-glucose in mouse models of ovarian cancer report that the compound significantly improves the effectiveness of the chemotherapy drug, carboplatin.